SGMT
Sagimet Biosciences Inc
$
9.580
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
10.0624
Open
9.630
VWAP
9.76
Vol
659.40K
Mkt Cap
308.43M
Low
9.450
Amount
6.43M
EV/EBITDA(TTM)
--
Total Shares
31.91M
EV
162.90M
EV/OCF(TTM)
--
P/S(TTM)
--
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
--
--
-0.544
+20.91%
--
--
-0.534
+6.79%
--
--
-0.570
+1.79%
Estimates Revision
The market is revising No Change the revenue expectations for Sagimet Biosciences Inc. (SGMT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 209.03%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-7.86%
In Past 3 Month
Stock Price
Go Up
+209.03%
In Past 3 Month
6 Analyst Rating
283.61% Upside
Wall Street analysts forecast SGMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMT is 36.75 USD with a low forecast of 25.00 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
283.61% Upside
Current: 9.580
Low
25.00
Averages
36.75
High
67.00
283.61% Upside
Current: 9.580
Low
25.00
Averages
36.75
High
67.00
Wedbush
NULL -> Outperform
initiated
$28
2025-08-11
New
Reason
Wedbush
Price Target
$28
2025-08-11
New
initiated
NULL -> Outperform
Reason
Wedbush initiated coverage of Sagimet Biosciences with an Outperform rating and $28 price target.
H.C. Wainwright
Brandon Folkes
initiated
$29
2025-08-07
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$29
2025-08-07
initiated
Reason
H.C. Wainwright analyst Brandon Folkes assumed coverage of Sagimet Biosciences with a Buy rating and $29 price target. The company is has a potential best-in-class fatty acid synthase inhibitor platform with \"multiple shots on goal\" across a number of diseases, including near-term clinical catalysts in metabolic dysfunction-associated steatohepatitis and dermatology, the analyst tells investors in a research note.
Canaccord
Edward Nash
Buy
initiated
$28
2025-07-24
Reason
Canaccord
Edward Nash
Price Target
$28
2025-07-24
initiated
Buy
Reason
Canaccord analyst Edward Nash initiated coverage of Sagimet Biosciences with a Buy rating and $28 price target.
JonesResearch
Debanjana Chatterjee
Buy
maintain
$15 -> $27
2025-06-05
Reason
JonesResearch
Debanjana Chatterjee
Price Target
$15 -> $27
2025-06-05
maintain
Buy
Reason
JonesResearch analyst Debanjana Chatterjee raised the firm's price target on Sagimet Biosciences to $27 from $15 and keeps a Buy rating on the shares. The company reported a positive readout from denifanstat's Ascletis-partnered Phase 3 acne program, the analyst tells investors in a research note. The firm says its check-in with acne doctor John Barbieri from Harvard Medical School suggests a "highly competitive profile" for FASN inhibition in acne. It now has increased confidence in the mechanism of action as well as the drug's market size.
Oppenheimer
Outperform
to
Outperform
downgrade
$30 -> $25
2025-05-12
Reason
Oppenheimer
Price Target
$30 -> $25
2025-05-12
downgrade
Outperform
to
Outperform
Reason
Oppenheimer lowered the firm's price target on Sagimet Biosciences to $25 from $30 and keeps an Outperform rating on the shares.
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$32
2025-03-13
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$32
2025-03-13
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Sagimet Biosciences Inc (SGMT.O) is -4.45, compared to its 5-year average forward P/E of -2.31. For a more detailed relative valuation and DCF analysis to assess Sagimet Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.31
Current PE
-4.45
Overvalued PE
-0.84
Undervalued PE
-3.78
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.02
Current EV/EBITDA
-1.71
Overvalued EV/EBITDA
0.55
Undervalued EV/EBITDA
-0.59
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
17.76
Current PS
253.54
Overvalued PS
75.28
Undervalued PS
-39.76
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
+12.62%
-11.93M
Operating Profit
FY2025Q2
YoY :
-100.00%
N/A
Net Income after Tax
FY2025Q2
YoY :
+28.00%
-0.32
EPS - Diluted
FY2025Q2
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 333.39% over the last month.
Sold
0-3
Months
772.2K
USD
3
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
7.3K
Volume
1
6-9
Months
428.9K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 333.39% over the last month.
Sold
0-3
Months
772.2K
USD
3
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SGMT News & Events
Events Timeline
2025-08-13 (ET)
2025-08-13
07:35:07
Sagimet Biosciences announces anticipated upcoming milestones
2025-08-13
07:34:23
Sagimet Biosciences reports Q2 EPS (32c), consensus (50c)
2025-05-08 (ET)
2025-05-08
06:16:13
Sagimet Biosciences reports Q1 EPS (56c), consensus (69c)
Sign Up For More Events
Sign Up For More Events
News
9.5
08-13NASDAQ.COMPinnedSagimet Biosciences Tops Q2 EPS Forecast
9.5
08-13NASDAQ.COMPinnedSagimet Biosciences Inc Q2 Loss Increases, But Beats Estimates
4.0
07-25TipRanks3 Best Stocks to Buy Now, 7/25/2025, According to Top Analysts
Sign Up For More News
People Also Watch
QUIK
Quicklogic Corp
6.000
USD
+3.09%
TELO
Telomir Pharmaceuticals Inc
1.600
USD
+3.23%
NEOV
NeoVolta Inc
4.090
USD
-13.35%
MRAM
Everspin Technologies Inc
6.350
USD
+0.79%
MMLP
Martin Midstream Partners LP
3.430
USD
-0.29%
ACU
Acme United Corp
44.580
USD
+2.72%
AMTX
Aemetis Inc
2.750
USD
-0.72%
TSQ
Townsquare Media Inc
6.980
USD
-0.57%
CTGO
Contango ORE Inc
21.690
USD
-2.87%
FAQ
What is Sagimet Biosciences Inc (SGMT) stock price today?
The current price of SGMT is 9.58 USD — it has increased 0.31 % in the last trading day.
What is Sagimet Biosciences Inc (SGMT)'s business?
What is the price predicton of SGMT Stock?
What is Sagimet Biosciences Inc (SGMT)'s revenue for the last quarter?
What is Sagimet Biosciences Inc (SGMT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Sagimet Biosciences Inc (SGMT)'s fundamentals?
How many employees does Sagimet Biosciences Inc (SGMT). have?